Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did you do a market order or limit order? If you do a market order which I have done in the past, they jacked the price on me on the OTC.
In the past I was a big believer in this company is from year 2009 to 2019, but after several years all that happened was that my $200,000 turned into $12,000. You would be better of burying your money in a coffee can in your backyard. Finally got out of this kaka and made my lost money back plus a surplus, so now I can retire.
Many of the officers had to take an approximate 20% pay cut in 2020, so maybe the pre-planned sales are making up for lost income?
Investing in the Dow is turning out to be like investing in ADXS the past 10 years. Genius W took out the uptick rule, so waiting to see what the shorts take down?
I live in Omaha, so watching closely.
That makes sense. If the government would fund it, they could probably develop a vaccine pretty quick with their onsite lab and production facility.
I managed to turn 200 K into 12 K after selling, but reinvested in another speculative non biotech stock. Like Bat, I will have to work into my sixties to survive this mismanaged arse rape. I still believe that the science will prevail after someone else takes over.
The short Grim Reaper appeared on the MB, so I sold the last 2 percent holdings and am bailing. It's been great corresponding with everyone the past 10 years. Hopefully the science moves forward with another company.
Cattdog, I sold 95 percent of my holdings at a loss during the recent run up so that I could invest it elsewhere where they have a CEO with an IQ over 70. Merck has a joint patent with ADXS on prostate with LM and PD1, so we need them more than they need us. IMO this will drop down faster than a meteor to either BK or another RS. I still believe in the tech, but IMO someone else will move it forward. Good luck Brother, it's been awesome corresponding for past 7 years!
I think that is a fair statement; as I have been following some of these posters for almost 10 years and I have seen their past values placed on the potential of the science. That being said; from experience I can say that you got to be tougher than hell to remain intact and to survive being an altar boy, in jail and being an ADXS shareholder.
No doubt on timing of announcement of RS, just like shelving Axal. IMO KB does not have LTSH interests at top of list.
Where can you purchase those pottery tickets?
Hope you are feeling better! I wonder if anything new is happening with infectious disease?
https://ir.advaxis.com/press-release/clinical-data-updates/advaxis-present-data-imvacs-immunization-and-vaccine-summit-use
I sincerely hope that you are correct. But I am approaching 10 years with ADXS, so I am fully expecting to get my nads kicked in, just like the other 3,530 days.
Sorry, bad link
Agree 100 percent. Sorry arse state of affairs. Our shares are not even worthy of TP until we get CEO with an IQ over 70
#7, the best thing to come out of California!
That may be a fair statement, although it may be a little premature to come to that conclusion. However it may play out that way and possibly show consistency from what we have seen in the past.
IMO that the future of this company probably lies in the design of AIM2CERV; which thankfully the company had the foresight to design the phase 3 in this fashion. Here is an excerpt from the AIM2CERV webpage:
The study is for women living with high-risk, locally-advanced cervical cancer (HRLACC) which is a cervical cancer that has an increased risk for returning following treatment with chemotherapy and radiation therapy. Your doctor can help determine if you meet the requirements for the study.
This study is being done to determine whether ADXS11-001, when taken after the completion of chemotherapy and radiation therapy, can help you live longer without the disease returning.
I was out Bar Harbor Maine on vacation in September of 2001, I was driving one night listening to a Patriots sports show on the radio, and it was right after Drew Bledsoe suffered that wicked chest injury. The broadcasters were talking about despair for the season, as they only had a sixth round pick back up QB from Michigan. Brady was a sixth round compensatory pick, so surely the NFL draft experts were correct? Later today we will continue to see how that worked out.
Thanks for posting the link.
This makes more sense now:
https://clinicaltrials.gov/ct2/show/NCT02531854
From Google Translate:
Nankai News Network (Reporter Wu Junhui correspondent Long Yuqing photography Wu Junhui) July 26, Academician of the American Academy of Sciences, Fellow of the American Inventors College, Professor of the Department of Microbiology and Molecular Cytology, University of California, Berkeley, Daniel Portoy (Daniel Portnoy) visited Nankai University and was invited to be a guest of the "111" series of life science colleges and had a discussion with the research backbone of the college.
Wang Lei, deputy secretary of the Party Committee of Nankai University, met with Daniel Portoy, and Party Secretary Yang Qingshan and President Cao Xuetao welcomed him to visit Nankai. Wang Lei introduced the history and characteristics of Nankai University, and introduced the development status of Nankai Life Science and the key research work in the field of microbiology. The two sides exchanged in-depth views on the establishment of teaching and research cooperation and joint research centers.
The "111" series of lecture forums is a brand academic activity hosted by the Party Committee Research and Development Department of Nankai University and undertaken by the School of Life Sciences. On the morning of the same day, Daniel Portoy was invited to the forum and presented an academic report entitled “Listeria monocytogenes: from pathogenic mechanisms to cancer immunotherapy”.
In the report, Daniel Portoy first detailed the epidemiological background of Listeria monocytogenes and its life cycle within the cell. In view of the ease of transformation and antigen expression of Listeria monocytogenes, he proposed the use of Listeria monocytogenes as a vaccine carrier to carry out immunotherapy against tumors, and confirmed the immunotherapy in a number of clinical cases. Small cell lung cancer, ovarian cancer, cervical cancer and mesothelioma have promising treatments. He further shared the mechanism by which intracellular Listeria monocytogenes are recognized by macrophages, and the efflux pump system of Listeria monocytogenes can activate the STING immune pathway to control cytokine expression in the host by secreting c-di-AMP. Progress in research.
Daniel Portnoy graduated from Stanley Falkow, a researcher at the Institute of Modern Molecular Pathogenic Microbiology, and is involved in the pathogenesis of Yersinia pestis, and the world's first identification of type III secretion. The system secretes the virulence protein "Yops". He then completed postdoctoral training at the Zanvil Cohn Fellowship at Rockefeller University, where he focused on macrophage Fc receptors and lysosomal proteases.
As a world-renowned pathogenic microbiologist, Daniel Portoy has pioneered a research platform for Listeria monocytogenes, with pioneering research in its pathogenesis, bacterial genetics, cell biology and immunology. He paid great attention to the training of young researchers. He has trained 18 professors, 13 of whom are at the top research universities in the United States, such as Harvard University and Cornell University. He is one of the most and most active microbiologists in the United States.
Daniel Portoy has an outstanding research contribution in the field of pathogenic microorganisms. He has published more than ten articles on Nature, Science, Cell and more than 20 articles on American Science Progress (PNAS) and has served as a member of several academic journals. At the same time, as an inventor, Daniel Portoy has 19 patents and 2 patents. The important findings based on the L. monocytogenes vaccine presentation platform and the cyclic dinucleotide (CDN)-Sting pathway have laid the foundation for two US-listed oncology immunotherapy companies. He also made outstanding contributions to the development of new infectious diseases and cancer vaccines.
Keywords : Liszt Shanzeng Nankai University
https://translate.google.com/
Thanks for sharing; I was not aware of this:
“The assessment of the TNFa and IFN-? response based on data from eight of the anticipated nine patients to be enrolled in stage 1 confirmed that the clinical study has already met the target for the overall rate of vaccine-induced T-cell response, paving the way for us to progress to stage 2,” said the study’s lead investigator Andrew G. Sikora, MD, PhD, of the Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery at Baylor College of Medicine. “
https://ir.advaxis.com/press-release/clinical-data-updates/advaxis-announces-phase-2-head-and-neck-cancer-study-axal
Urban legend has it that they took cash down to $20, before the first RS, but I am unable to find a link to support this alleged legend. But I swear on a case of beer that this may have been mentioned at ribbon cutting ceremony.
First leg was for very low almost mouse strength dosage, the patent filing may shed light on the second leg?
https://patents.justia.com/patent/8956621
Here is an excerpt:
Safety and Efficacy of LM-LLO-E7 for the Treatment of Cervical Intraepithelial Neoplasia
Advaxis has treated 45 patients with grade 2 or 3 Cervical Intraepithelial Neoplasia (cervical dysplasia) thus far in a trial designed to treat 120 patents. Three treatment groups of 40 patients each are comprised of 10 patients who get placebo on a randomized basis and 30 patients who get active drug at 5.107, 3.3×108 or 1×109 cfu. A safety run in of 3 patients is conducted for each dosage group and these patients receive the active drug. The remaining 37 patients are randomized to either placebo or active drug at a ratio of 3 active patients for each placebo patient. The trial involves the administration of Advaxis agent ADXS11-001 directed against HPV 16-E7 3 times at 28 day intervals followed by a surgical LEEP procedure 6 months after the initial dose. Pretreatment biopsy samples are compared with post treatment LEEP surgery specimens for an assessment of histologic response.
The objective of this study was to see whether a vaccine regimen can replace surgery. Aside from the pain, bleeding, and other aspects of surgery, the removal of a portion of the cervix often leads to an inability to come to a full term pregnancy (“incompetent cervix”). A pharmaceutical treatment would thus be preferential to surgery. Especially one that induces immunologic memory against the etiologic agent that causes cervix cancer, HPV, in a manner that protects against recurrence.
At the present time the random code has not been broken, however of the 18 treated patients 3-4 patients have receive placebo and 14-15 patients have received active drug. The average spontaneous remission rate in this population is approximately 25%, and 4-5 patients spontaneously remit assuming the experimental agent was ineffective, but in the 18 patients treated to date, irrespective of treatment, 14 have remitted. Thus, a therapeutic effect of the agent on the precancerous condition of CIN is being observed.
https://www.biospace.com/article/releases/advaxis-inc-reports-positive-phase-ii-trial-results-/
How come you have waited over 6 years, if you truly feel that this trial was a failure?
Was not the low dosage leg at something like a mouse strength dosage?
If I remember correctly too many women dropped out of the mid dosage phase; so the results were inconclusive. But we did have a glimpse on the old Yahoo MB of the mythical mysterious patent filing.
Hats off to you, as you had the 0.19 pegged. Are you the MM or the Nostradamus of our time? I live West of the Oracle, so I sent him a smoke signal.
FDA guidance, wonder if this may possibly affect AIM2CERV revisions?
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
FBG, I respect you since you have been here since at least 2010 when Sarah was busting our nards about JAZZ at $8.
IMO first gen vaccines are probably going to show best results with non-metastic population. Which I think Ken was probably confirming during recent conference
Will also possibly work with LM as the delivery vehicle?
"Nevertheless, although the mRNA delivery system was more effective than the plasmid DNA delivery strain, it was still not as effective as the Listeria strains that endogenously expressed and secreted the tumor antigen [56]. Clearly, despite a decade of research developing Listeria monocytogenes as a vector for the delivery of eukaryotic expression systems, further improvements are required for these strategies to exceed or match the effectiveness of Listeria as a protein delivery system (55, 56). Nevertheless such efforts are important since they could overcome some of the difficulties associated with expression and secretion of large, hydrophobic proteins by Listeria, thus broadening the targets for Listeria based tumor immunotherapy."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411241/
Could possibly be game over, or it possibly could be the best thing that ever happened. IMO this was probably a licensing nightmare with NEO possibly containing parts of other constructs. Hopefully some company with a CI steps up to the plate.
Agree on that. If they drop this to a dime, I may buy enough to be an insider.
Sounds like my ex-wife, although she cost me less than ADXS.
But it's not game over yet.
I look for this to possibly hit a dime prior to a deal possibly being announced in February or March. I am waiting for a 3 or 4 million volume day for about a week; that's what I am going in buy in speculating that a deal will possibly be announced shortly thereafter. It's a gamble, but I am going to take it. I am not going to sell my current shares now and try to buy back in; just too risky to time it without knowing what is going on behind the scenes.
I concur, in my uneducated opinion; LM will continue to evolve, and may provide the best vehicle to trigger the immune system. Hopefully someday we get to tackle infectious diseases.
Check out the list of trials in Table 1. Sorry if this has already been discussed; but I did not know about the HPV+/NSCLC?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160973/
Sorry to hear about your dog. I just recently lost my rat terrier to cancer. Dogs are unconditional love, and it's tough to see them suffering.
Zolt, that sound delicious. I use the trash can because it cooks faster (1 pound per 6 minutes) and frees up the oven. I learned the mustard rub from a German chef; keeps the meat from drying out and does not leave any mustard flavor in my opinion, much easier IMO than brine-ing a turkey. Although the heat will kill the grass, so need to take that into account.
You also have to pre-season (i.e. pre-heat a day prior with vegetable oil) the galvanized trash can; just like you would for a painted smoker or grill.
Have a Great Turkey Day!
http://www.thetrashcanturkey.com/index.html
Likewise, Happy Thanksgiving to everyone. Doing a trash can turkey tomorrow.
Yes, seasoning under the skin. And mustard brushed on the outside to keep the bird moist